Abstract

LDL is the most abundant cholesterol transport vehicle in plasma and a major prognostic indicator of atherosclerosis. Hepatic LDL receptors limit circulating LDL levels, since cholesterol internalized by the liver can be excreted. As such, mechanisms regulating LDL receptor expression in liver cells are appealing targets for cholesterol-lowering therapeutic strategies. Activation of HepG2 cells with phorbol esters enhances LDL receptor mRNA levels through transcriptional and posttranscriptional mechanisms. Here, we show that 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced stabilization of receptor mRNA requires the activity of protein kinase C and is accompanied by activation of the major mitogen activated protein kinase pathways. Inhibitor studies demonstrated that receptor mRNA stabilization is independent of the extracellular signal-regulated kinase or p38(MAPK), but requires activation of the c-Jun N-terminal kinase (JNK). An essential role for JNK in stabilizing receptor mRNA was further confirmed through small interfering RNA (siRNA) experiments and by activating JNK through two protein kinase C-independent mechanisms. Finally, prolonged JNK activation increased steady-state levels of receptor mRNA and protein, and significantly enhanced cellular LDL-binding activity. These data suggest that JNK may play an important role in posttranscriptional control of LDL receptor expression, thus constituting a novel mechanism to enhance plasma LDL clearance by liver cells.

Highlights

  • LDL is the most abundant cholesterol transport vehicle in plasma and a major prognostic indicator of atherosclerosis

  • protein kinase C (PKC) activation stabilizes LDL receptor mRNA concomitant with activation of mitogen-activated protein kinase (MAPK) pathways Previous studies indicated that the abundance and stability of LDL receptor mRNA were transiently enhanced in HepG2 cells following treatment with phorbol esters [15, 18], presumably involving activation of the PKC pathway

  • Activation of p38MAPK may exert a negative influence on extracellular signal-regulated kinase (ERK)-dependent induction of receptor gene transcription, because the p38MAPK inhibitor SB202190 augments LDL receptor mRNA levels in HepG2 cells, accompanied by enhancement of ERK phosphorylation [37]

Read more

Summary

Introduction

LDL is the most abundant cholesterol transport vehicle in plasma and a major prognostic indicator of atherosclerosis. Since cholesterol synthesis is restricted principally to the liver, these compounds deplete intracellular cholesterol in this tissue, which in turn enhances transcription of the LDL receptor gene through activation of the sterol-regulatory element binding protein (SREBP) family of transcription factors [12]. These examples demonstrate that therapeutic strategies that increase the expression of functional LDL receptors in liver cells improve LDL clearance from the circulation, which in turn

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call